Cardinal Capital Management Buys 431 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cardinal Capital Management boosted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.6% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 12,499 shares of the specialty pharmaceutical company’s stock after purchasing an additional 431 shares during the quarter. Cardinal Capital Management’s holdings in Jazz Pharmaceuticals were worth $1,393,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in JAZZ. Bleakley Financial Group LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $227,000. nVerses Capital LLC acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter worth $290,000. CFM Wealth Partners LLC raised its position in shares of Jazz Pharmaceuticals by 59.5% during the 3rd quarter. CFM Wealth Partners LLC now owns 4,184 shares of the specialty pharmaceutical company’s stock valued at $504,000 after acquiring an additional 1,560 shares during the last quarter. Benson Investment Management Company Inc. acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $4,082,000. Finally, Wedge Capital Management L L P NC bought a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth $32,497,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on JAZZ shares. Royal Bank of Canada increased their target price on Jazz Pharmaceuticals from $174.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Wells Fargo & Company reduced their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. UBS Group lowered their target price on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research note on Tuesday, July 2nd. Robert W. Baird reduced their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Finally, Needham & Company LLC restated a “buy” rating and issued a $205.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $173.14.

Jazz Pharmaceuticals Stock Up 0.4 %

NASDAQ:JAZZ opened at $115.04 on Friday. The stock has a 50-day simple moving average of $110.88 and a 200 day simple moving average of $109.79. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $137.38. The company has a market cap of $7.25 billion, a PE ratio of 23.72, a PEG ratio of 1.34 and a beta of 0.57. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.87. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. On average, sell-side analysts expect that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.